Joshua Daniel Brandstadter, MD, PhD, MSc
Hematology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 4th Floor West
Penn Medicine Provider

About me

  • Director, Clinical Research, Center for Cytokine Storm Treatment & Laboratory
  • Assistant Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
  • Instructor A of Medicine (Hematology-Oncology)

Dr. Joshua Brandstadter is a physician-scientist who cares for patients with lymphoma and rare blood disorders, particularly Castleman Disease and histiocytic disorders. In addition to his clinical work, Dr. Brandstadter pursues laboratory-based translational research and serves as Director of Clinical Research for the Center for Cytokine Storm Treatment & Laboratory.

Education and training

  • Medical School: Duke University School of Medicine
  • Residency: Hospital of the University of Pennsylvania
  • Fellowship: Hospital of the University of Pennsylvania

What my patients think about me

Average Rating

35 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

September 2025
dr. brandstadter is specialized in treating castleman disease.
July 2025
dr. brandstadter is very knowledgeable and understanding when it came to my concerns.
June 2025
best cancer doctor in the northeast. i had a very rare blood cancer and Dr Brandstadter made me feel ok and normal.
January 2025
an amazing doctor, who loves his patients and his job. would always recommend

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Brandstadter is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

McHugh K, Huang Y, Austin B, Borys L, Irvine A, Alapat D, Bagg A, Chadburn A, Lechowicz MJ, Lim M, Srkalovic G, van Rhee F, Fajgenbaum D, Zhang L, Brandstadter J Idiopathic multicentric castleman disease unresponsive to one IL-6 inhibitor may respond to another IL-6 inhibitor , American Society of Hematology Annual Meeting, Orlando, FL: 2025


Kurz L, Lutge M, De Martin A, Cheng H-W, Bugar E, Stanossek Y, Meili S, Brandstadter JD, Maillard I, Onder L, Ludewig B A common progenitor gives rise to fibroblastic reticular cells and vascular smooth muscle cells in murine lymph nodes , Journal of Experimental Medicine, 2(223): 2025,e20242300


Steven Rowe, Mariam Goubran, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Bridget Austin, Kathleen McNicholas, Marley Blommers, Junyan Shi, Lisa K Peterson, Lusia Sepiashvili, Andre Mattman, Joshua D Brandstadter, David C Fajgenbaum, Luke Y C Chen Ferritin, C-Reactive Protein, and Soluble CD25 Distinguish TAFRO From HLH , Am J Hematol: 2025


Mechthild Lütge, Lisa Kurz, Yves Stanossek, Samuel Meili, Hung-Wei Cheng, Angelina De Martin, Joshua Brandstadter, Ivan Maillard, Mark D Robinson, Sandro J Stoeckli, Natalia B Pikor, Lucas Onder, Burkhard Ludewig Fibroblastic reticular cells form reactive myeloid cell niches in human lymph nodes , Science Immunology, 10(107): 2025,eads6820


Dave Maurice De Sousa, Eric Perkey, Laure Le Corre, Salix Boulet, Daniela Gómez Atria, Anneka Allman, Frédéric Duval, Jean-François Daudelin, Joshua D Brandstadter, Katlyn Lederer, Sarah Mezrag, Livia Odagiu, Myriam Ennajimi, Marion Sarrias, Hélène Decaluwe, Ute Koch, Freddy Radtke, Burkhard Ludewig, Christian W Siebel, Ivan Maillard, Nathalie Labrecque Early Notch signals from fibroblastic reticular cells program effector CD8+ T cell differentiation , J Exp Med, 5(222): 2025,e20231758


Sheila K Pierson, Joshua D Brandstadter, Drew Torigian, Adam Bagg, Mary Jo Lechowicz, Daisy Alapat MD, Corey Casper, Amy Chadburn, Shanmuganathan Chandrakasan, Angela Dispenzieri, Alexander Fosså, Christian Hoffmann, Makoto Ide, Razelle Kurzrock, Sudipto Mukherjee, Sunita D Nasta, José-Tomás Navarro, Ariela Noy, Eric Oksenhendler, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Matthew J Streetly, Raymond Siu Ming Wong, Lu Zhang, Megan S Lim, Gordan Srkalovic, Frits van Rhee, David C Fajgenbaum Characterizing the heterogeneity of Castleman disease and oligocentric subtype: Findings from the ACCELERATE registry , Blood Advances: 2025


Anneka Allman, Brian T Gaudette, Samantha Kelly, Nagham Alouche, Léolène J Carrington, Eric Perkey, Joshua D Brandstadter, Riley Outen, Ashley Vanderbeck, Katlyn Lederer, Yeqiao Zhou, Robert B Faryabi, Tanner F Robertson, Janis K Burkhardt, Anastasia Tikhonova, Iannis Aifantis, Leonardo Scarpellino, Ute Koch, Freddy Radtke, Mechthild Lütge, Angelina De Martin, Burkhard Ludewig, Lena Tveriakhina, Achim Gossler, Lluc Mosteiro, Christian W Siebel, Daniela Gómez Atria, Sanjiv A Luther, David Allman, Ivan Maillard Splenic fibroblasts control marginal zone B cell movement and function via two distinct Notch2-dependent regulatory programs , Immunity, 58(1): 2025


Brandstadter JD, Lutge M, Lim MS, Bagg A, Miller ID, Gonzalez MV, Austin B, Priore SF, Ludewig B, Fajgenbaum DC, Maillard I. Myofibroblast to T-Zone Reticular Cell Ratio Identifies Unicentric Castleman Disease Lymph Nodes , American Society of Hematology Annual Meeting, San Diego, CA.: 2024


Bustamante MS, Pierson SK, Ren Y, Bagg A, Brandstadter JD, Srkalovic G, Mango N, Alapat D, Lechowicz MJ, Li H, Van Rhee F, Lim MS, Fajgenbaum DC. Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease , Haematologica, 109: 2024,2196-2206


Shyamsundar S, Pierson SK, Connolly CM, Teles M, Segev DL, Werbel WA, van Rhee F, Casper C, Brandstadter JD, Noy A, Fajgenbaum DC. Castleman disease patients report mild COVID-19 symptoms and mount a humoral response to SARS-CoV-2 vaccination , Blood Neoplasia, 1(1): 2024,100002. doi: 10.1016/j.bneo.2024.100002.


View all publications